UBS Maintains Neutral on Sabra Health Care REIT, Lowers Price Target to $20
UBS analyst Michael Goldsmith maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Neutral and lowers the price target from $21 to $20.
Stocks · News reference
Raymond James Upgrades Sabra Health Care REIT to Market Perform
Raymond James analyst David Rodgers upgrades Sabra Health Care REIT (NASDAQ:SBRA) from Underperform to Market Perform.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Lowers Price Target to $21
Barclays analyst Richard Hightower maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Equal-Weight and lowers the price target from $23 to $21.
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Raises Price Target to $23
Barclays analyst Richard Hightower maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Equal-Weight and raises the price target from $21 to $23.
Baird Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $21
Baird analyst Vikram Malhotra maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Neutral and raises the price target from $20 to $21.